Crossmark

A modular platform for targeted RNAi therapeutics

Crossref DOI link: https://doi.org/10.1038/s41565-017-0043-5

Published Online: 2018-01-29

Published Print: 2018-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kedmi, Ranit

Veiga, Nuphar

Ramishetti, Srinivas

Goldsmith, Meir

Rosenblum, Daniel

Dammes, Niels

Hazan-Halevy, Inbal

Nahary, Limor

Leviatan-Ben-Arye, Shani

Harlev, Michael

Behlke, Mark

Benhar, Itai

Lieberman, Judy

Peer, Dan
License Information

Text and Data Mining valid from 2018-01-29
More Information

Article History

Received: 8 August 2016

Accepted: 5 December 2017

First Online: 29 January 2018

Competing interests

: M.B. is an employee of Integrated DNA Technologies, Inc. J.L. is on the Scientific Advisory Board of Alnylam Pharmaceuticals. D.P. declares financial interests in Quiet Therapeutics. The rest of the authors declare no competing financial interests.